ACTA2 and Dupuytren Contracture: In myofibroblasts from Dupuytren’s disease patients, SGC-CBP30 and I-CBP112 were used to validate CREBBP and EP300 as key regulators of the profibrotic phenotype in myofibroblasts by decreasing the expression of the profibrotic genes ACTA2 and COL1A1 [92].